Regulus Therapeutics (RGLS) Tops Q2 EPS by 4c

Regulus Therapeutics (NASDAQ: RGLS) reported Q2 EPS of ($0.37), $0.04 better than the analyst estimate of ($0.41).

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Air France-KLM (AF:FP) (AFLYY) PT Raised to EUR13.50 at UBS
• Citi sees this stock as primary lithium demand beneficiary, upgrades to Buy